About TomegaVax
TomegaVax is a company based in Beaverton (United States) founded in 2011 was acquired by Vir Biotechnology in January 2017. TomegaVax offers products and services including Mobile Home Sales, Escrow Services, and Advertising Services. TomegaVax operates in a competitive market with competitors including Moderna, Adaptive Biotechnologies, Generate Biomedicines, HOOKIPA Pharma and Brii Biosciences, among others.
- Headquarter Beaverton, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
$1.98 M (USD), Grant
Mar 03, 2017
-
Investors
Vir Biotechnology
& 1 more
-
Employee Count
Not available
-
Acquired by
Vir Biotechnology
(Jan 06, 2017)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of TomegaVax
TomegaVax offers a comprehensive portfolio of products and services, including Mobile Home Sales, Escrow Services, and Advertising Services.
Facilitates buying and selling of mobile homes in Oregon areas
Provides in-house escrow for home transactions and lending
Covers ads for home listings and buyer outreach
Funding Insights of TomegaVax
Investors in TomegaVax
TomegaVax has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Vir Biotechnology and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked | |
|
Developer of therapeutics for the treatment of infectious diseases
|
Locked | Locked | Locked |
Investor details for TomegaVax
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by TomegaVax
Investment portfolio details for TomegaVax
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - TomegaVax
Detailed financials for TomegaVax
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Tomegavax Comparisons
Peer comparison for TomegaVax
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of TomegaVax
TomegaVax operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Adaptive Biotechnologies, Generate Biomedicines, HOOKIPA Pharma and Brii Biosciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Clinical diagnostics and drug discovery for immune diseases are provided.
|
|
| Locked | Locked | Locked |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
|
| Locked | Locked | Locked |
Developer of immunotherapies for the treatment of infectious diseases and cancer
|
|
| Locked | Locked | Locked |
Developer of biologics to treat hepatitis B infection
|
|
| Locked | Locked | Locked |
Developer of computationally designed VLP vaccines for treating multiple infections
|
Detailed competitors of TomegaVax
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Tomegavax
Complete news archive for TomegaVax
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about TomegaVax
TomegaVax was founded in 2011 and raised its 1st funding round 1 year after it was founded.
TomegaVax is headquartered in Beaverton, United States. It is registered at Beaverton, Oregon, United States.
TomegaVax is an immunotherapy company focussed on developing vaccines for viral infections. It has developed a vaccine technology which uses a cytomegalovirus (CMV) vector and provides continuous low-level antigen presentation to maintain an active T-cell-mediated immune shield. It currently has preclinical and clinical CMV-based vaccine programs for chronic and recurring viral infections including Human Immunodeficiency Virus (HIV), Human Papillomavirus (HPV), Hepatitis B Virus (HBV) and Herpes Simplex Virus (HSV). It also states that the vaccines can not only prophylactically protect against infection but also control existing infections. It claims that these CMV-based vaccines have also demonstrated pre-clinical efficacy in animal models of Tuberculosis (TB), Malaria, Ebola Virus and cancers including prostate cancer and melanoma.
TomegaVax's top competitors include Moderna, Adaptive Biotechnologies and Generate Biomedicines.
TomegaVax offers Mobile Home Sales, Escrow Services, and Advertising Services.
TomegaVax has 2 investors. Key investors include Vir Biotechnology, and HHS.